Allergan Aesthetics Reports Improved Satisfaction With Facial Appearance Following Aesthetic Treatment in Two Studies of Patients on GLP-1 Medications
Allergan Aesthetics, an AbbVie company, reported positive results from two Phase 4 studies of aesthetic treatment in adults on GLP-1 weight-loss medications, presented at the ASDS 2026 Annual Meeting. In HARMONY IN DIVERSITY (30 adults), combined HA injectables, onabotulinumtoxinA and skincare produced a statistically significant 42.4-point mean improvement in FACE-Q Satisfaction With Facial Appearance; HALO interim data (25 of 75 participants) showed 39.6-point improvement and 95.7% satisfaction with looking like themselves.
Key figures
- Phase Of Trial
- Phase 4
- Halo total n
- 75
- Halo interim n
- 25
- Harmony cohort2 n
- 30
- Faceq improvement halo
- 39.6 points
- Pct satisfied natural look
- 82.6%
- Faceq improvement harmony cohort2
- 42.4 points
- Pct satisfied looked like themselves
- 95.7%
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.